Novo Nordisk

News

Novo Nordisk ups forecasts after Q1 profit boost

After an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast after posting better than expected Q1 earnings and sales.

News

Gilead pushes on with NASH partnership with Novo Nordisk

Gilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – but after

News

Novo Nordisk’s semaglutide effective against obesity in new ...

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the

News

The liver is a vital organ of the digestive system present in vertebrates and some other animals. It has a wide range of functions, including detoxification, protein synthesis, and production of biochemicals necessary for digestion.

High hopes as Inventiva takes NASH contender into phase 3

Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, as the company prepares for the launch of a phase 3 trial in s

News

Novo Nordisk’s gene silencing alliance with Dicerna bears fi...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometaboli

News

Lilly surges on positive phase 3 readout from diabetes conte...

Eli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be vindicated, according to its first phase 3 trial readout.<

Novo Nordisk ups forecasts after Q1 profit boost

Gilead pushes on with NASH partnership with Novo Nordisk

Novo Nordisk’s semaglutide effective against obesity in new ...

High hopes as Inventiva takes NASH contender into phase 3

Novo Nordisk’s gene silencing alliance with Dicerna bears fi...

Lilly surges on positive phase 3 readout from diabetes conte...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

Novo Nordisk

Editor's Picks